New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
06:34 EDTALXNAlexion sees FY13 non-GAAP EPS $2.82-$2.92, consensus $2.81
Sees FY13 $1.49B-$1.51B, consensus $1.49B. R&D expenses are expected to be in the range of $285M-$295M, and SG&A expenses in the range of $425M-$435M. The non-GAAP effective tax rate, reported on a cash tax liability basis, is expected to be in the range of 7%-9%.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
08:59 EDTALXNOn The Fly: Pre-Market Movers
Subscribe for More Information
06:43 EDTALXNAlexion raises 2014 adj EPS view to $4.75-$4.85 from $4.37-$4.47
Subscribe for More Information
06:41 EDTALXNAlexion reports Q1 adjusted EPS $1.16 ex-items, consensus $1.26
Subscribe for More Information
06:25 EDTALXNAlexion begins multinational registration trials of eculizumab
Alexion initiated a single, multinational, placebo-controlled trial to evaluate the safety and efficacy of eculizumab - Soliris - in patients with relapsing neuromyelitis optica, a life-threatening, ultra-rare neurologic disorder. Alexion also initiated a single, multinational, placebo-controlled trial in patients with refractory generalized myasthenia gravis, another rare and debilitating neurologic disorder. Currently, there are no approved treatments for NMO. Soliris is currently approved in the U.S., European Union, Japan and other countries for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Soliris is not approved in any country for the treatment of NMO or MG.
April 23, 2014
07:00 EDTALXNTerrapinn to hold a conference
Subscribe for More Information
06:37 EDTALXNAlexion's Soliris granted Orphan Drug Designation by European Commission
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use